<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2072-0351-5602</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-5602</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Раннее назначение инсулинотерапии при сахарном диабете типа 2</article-title><trans-title-group xml:lang="en"><trans-title>The early use of insulin in type 2 diabetes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Леви</surname><given-names>Филип</given-names></name><name name-style="western" xml:lang="en"><surname>LEVY</surname><given-names>PHILIP</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Clinical Professor of Medicine I University of Arizona College of Medicine</institution></aff><aff xml:lang="en"><institution>Clinical Professor of Medicine I University of Arizona College of Medicine</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>15</day><month>06</month><year>2004</year></pub-date><volume>7</volume><issue>2</issue><issue-title>№2 (2004)</issue-title><fpage>10</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Леви Ф., 2004</copyright-statement><copyright-year>2004</copyright-year><copyright-holder xml:lang="ru">Леви Ф.</copyright-holder><copyright-holder xml:lang="en">LEVY P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/5602">https://www.dia-endojournals.ru/jour/article/view/5602</self-uri><abstract><p>Около 60-70% пациентов с СД типа 2 для посто янного контроля гликемии нуждаются в инсулинотерапии на долгосрочной основе. Инсулинотерапия часто не назначается в связи с существованием определенных барьеров и страхов как у пациентов, так и у врачей. Раннее назначение инсулина при наличии показаний очень важно в плане снижения частоты микрососудистых осложнений диабета, включая ретинопа? тию, нейропатию и нефропатию. Нейропатия является основной причиной нетравматических ампутаций у взрослых пациентов. Ретинопатия ? ведущая причина слепоты у взрослых, а нефропатия ? основной фактор, приводящий к терминальной почечной недостаточности. Проспективное исследование по сахарному диабету в Великобритании (UKPDS) и исследование Kumamoto продемонстрировали положительный эффект инсулинотерапии в плане снижения риска микрососудистых осложнений, а также выраженную тенденцию (хотя ста? тистической достоверности показано не было) к улучшению прогноза в плане макрососудистых осложнений.</p></abstract><trans-abstract xml:lang="en"><p>60?70% of all patients with Type 2 Diabetes Mellitus will ultimately require insulin therapy for the management of their diabetes. Irisulin may be used alone, or in combination with oral agents. The early use of insulin can be very important in decreasing the incidence of micro-vascular complications and in helping to delay the onset of macro-vascular complications. The United Kingdom Prospective Diabetes Study and the Kumamoto Study have shown the beneficial effects of good glucose control in type 2 diabetes mellitus. The DECODE study has related overall mortality to the level of glucose control and specifically to the postprandial glucose. The American Association of Clinical Endocrinologists has established a goal of 6.5% or less for HgbAlc. The appropriate use of insulin will allow us to achieve this goal without causing the patient any undue harm. There are many barriers to insulin therapy including psychological barriers of both the patient and the doctor, and unrealistic fears of both insulin therapy and therapy with self-administered injections. These barriers will be discussed as well as methods to overcome them. Insulin therapy is beneficial and has no long term adverse effects. The incidence of severe hypoglycemia is extremely low in type 2 diabetes. Weight gain is minimal. Insulin therapy by reducing glucose toxicity may also increase the effectiveness of oral anti-hyperglycemic agents. The physician taking care of patients with diabetes should be aggressive and should have no fears of initiating insulin therapy. Insulin dosage is flexible and good control is possible in most patients. The most common use of insulin in type 2 diabetes is as an add-on to oral agents if control with oral agents alone is unsatisfactory. Frequently this involves the use of a single dose of intermediate or long acting insulin or an insulin mixture in the evening. If control is not attained with a single dose, then the patient can be placed on an insulin mixture 2 or 3 times a day. An alternative would be a short acting insulin analogue prior to each meal with a longer acting insulin given 1 or 2 times a day. Titration schedules for insulin dosing will be presented. Insulin available in Russia will be listed along with some guidelines on using these insulins. Increasing the use of insulin and starting insulin earlier in type 2 diabetes will lead to better control of diabetes, increased patient compliance, and decreased long-term complications of diabetes mellitus.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инсулинотерапия</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>лечение</kwd><kwd>гликемический контроль</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">UKPDS Group. Lancet. 1 998; 352:837-852 6.</mixed-citation><mixed-citation xml:lang="en">UKPDS Group. Lancet. 1 998; 352:837-852 6.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">DCCT Research Group. Diabetes 1995; 34:222-234</mixed-citation><mixed-citation xml:lang="en">DCCT Research Group. Diabetes 1995; 34:222-234</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ohkubo Y et al. DiabResClinPract 1 995;28 :103-1 17</mixed-citation><mixed-citation xml:lang="en">Ohkubo Y et al. DiabResClinPract 1 995;28 :103-1 17</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Heineman, et al Diabet Med. 1 996; 1 3:625-629</mixed-citation><mixed-citation xml:lang="en">Heineman, et al Diabet Med. 1 996; 1 3:625-629</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">DECODE Study Group. Lancet. 1999,354:617-621</mixed-citation><mixed-citation xml:lang="en">DECODE Study Group. Lancet. 1999,354:617-621</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Garvey TW et al Diabetes. 1 985;34:222-234</mixed-citation><mixed-citation xml:lang="en">Garvey TW et al Diabetes. 1 985;34:222-234</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">American College of Endocrinology Concensus Conference on Guidelines for</mixed-citation><mixed-citation xml:lang="en">American College of Endocrinology Concensus Conference on Guidelines for</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Glycemic Control. Endocrine Practice.2002;8{Suppl 1 ):40-82</mixed-citation><mixed-citation xml:lang="en">Glycemic Control. Endocrine Practice.2002;8{Suppl 1 ):40-82</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
